Preliminary results from a phase II study of lenalidomide monotherapy in Relapsed/Refractory aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Wiemik, Peter H.
Lossos, Izidore
Tuscano, Joseph
Justice, Glen
Vose, Julie M.
Pietronigro, Dennis
Takeshita, Kenichi
Ervin-Haynes, Annette
Zeldis, Jerome B.
Habermann, Thomas M.
机构：
[1] Coll Med, Our Lady Canc Ctr, Bronx, NY 33152 USA
[2] Univ Miami, Sylvester Canc Ctr, Miami, FL 95817 USA
[3] Univ Calif Davis, Ctr Canc, Sacramento, CA USA
[4] Oncol Med Grp, Fountain Valley, CA 68182 USA
[5] Univ Nebraska, Omaha, NE USA
[6] Celgene Corp, Summit, NJ USA
[7] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
531
引用
收藏
页码：160A / 161A
页数：2
相关论文
共 50 条
  • [31] An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
    Witzig, T. E.
    Vose, J. M.
    Zinzani, P. L.
    Reeder, C. B.
    Buckstein, R.
    Polikoff, J. A.
    Bouabdallah, R.
    Haioun, C.
    Tilly, H.
    Guo, P.
    Pietronigro, D.
    Ervin-Haynes, A. L.
    Czuczman, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 (07) : 1622 - 1627
  • [32] Phase II study of oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma: Final results.
    Oki, Y
    McLauhlin, P
    Pro, B
    Hagemeister, FH
    Bleyer, A
    Loyer, E
    Younes, A
    BLOOD, 2004, 104 (11) : 684A - 684A
  • [33] Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Prichard, Mark
    Harris, Thomas
    Williams, Michael E.
    Densmore, John J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 983 - 995
  • [34] Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
    Weidmann, E
    Kim, SZ
    Rost, A
    Schuppert, H
    Seipelt, G
    Hoelzer, D
    Mitrou, PS
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1285 - 1289
  • [35] Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma
    Gillian M. Keating
    Drugs, 2016, 76 : 1579 - 1586
  • [36] Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
    Keating, Gillian M.
    DRUGS, 2016, 76 (16) : 1579 - 1586
  • [37] Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive non-Hodgkin's lymphoma results of multicenter phase II study
    Josting, A
    Sieniawski, M
    Staak, J
    Diehl, V
    Engert, A
    ANNALS OF ONCOLOGY, 2005, 16 : 183 - 183
  • [38] Phase II trial of Doxil® in patients with refractory/relapsed low-grade non-Hodgkin's lymphoma.
    Di Bella, NJ
    Khan, MM
    Dakhil, SR
    Logie, KW
    Marsland, TA
    Simon, SR
    Weinstein, RE
    BLOOD, 2000, 96 (11) : 236B - 236B
  • [39] Final results of the phase II trial of paclitaxel plus oral estramustine phosphate in patients with relapsed aggressive non-Hodgkin's Lymphoma.
    Borghaei, H
    Millenson, MM
    Schilder, RJ
    Rogatko, A
    Alden, M
    Wang, H
    Padavic-Shaller, KA
    Minnitti, C
    Smith, MR
    BLOOD, 2003, 102 (11) : 293B - 293B
  • [40] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
12345